The Microbiome and Inflammatory Bowel Disease: Is There a Therapeutic Role for Fecal Microbiota Transplantation?
The Microbiome and Inflammatory Bowel Disease: Is There a Therapeutic Role for Fecal Microbiota Transplantation?
复制标题
DOI：
10.1038/ajg.2012.93
复制
发表时间：
2012-10-01
影响因子：
9.8
通讯作者：
Zisman, Timothy L.
中科院分区：
文献类型：
--
作者：
Damman, Christopher J.;Miller, Samuel I.;Zisman, Timothy L.
炎症性肠病的病因学的一个假设是，改变的或致病的微生物群在遗传易感个体中引起炎症。了解微生物群在疾病发病机制中的作用可能会导致新的IBD治疗方法，旨在将肠道中的细菌转移回良性生态。益生菌在治疗溃疡性结肠炎（UC）方面有一定的疗效，但我们目前的治疗方案效力有限。粪便微生物群疗法（FMT）是一种新兴的治疗几种胃肠道和代谢疾病。它已被证明对治疗难治性艰难梭菌感染有效，并且有FMT成功治疗UC的病例报告。进一步的临床研究是合理的，可以通过粪便移植的小鼠模型来补充，其中变量可以被控制和操纵。
One hypothesis for the etiology of inflammatory bowel disease is that an altered or pathogenic microbiota causes inflammation in a genetically susceptible individual. Understanding the microbiota's role in the pathogenesis of the disease could lead to new IBD treatments aimed at shifting the bacteria in the gut back to eubiosis. Probiotics have some efficacy in the treatment of ulcerative colitis (UC), but our current repertoire is limited in potency. Fecal microbiota therapy (FMT) is an emerging treatment for several gastrointestinal and metabolic disorders. It has demonstrated efficacy in treating refractory Clostridium difficile infection, and there are case reports of FMT successfully treating UC. Further clinical studies are justified, and could be complemented by mouse models of fecal transplantation, in which variables can be controlled and manipulated.